December 22, 2025 · Form 4 insider transaction
Kaul Inderjit bought 364,504 shares of Minerva Neurosciences, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
25% of the option shall vest on November 14, 2026; an additional 45% of the option shall vest on the tenth day following the date of the Issuer's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the option shall vest on the tenth day following the date of the Issuer's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date.